Pfizer Inc. Stock
€22.31
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Pfizer
sharewise wants to provide you with the best news and tools for Pfizer, so we directly link to the best financial data sources.
Financials
News
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All
After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 sectors over the past six months.
In large part, that rebound was
This ETF Is Proof That the Healthcare Rebound Is Real
With well-publicized losses for companies including UnitedHealth Group (NYSE: UNH), Elevance Health (NYSE: ELV), and Wegovy and Ozempic maker Novo Nordisk (NYSE: NVO), the healthcare sector failed
These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever
The S&P 500 wrapped up 2025 with a total return of about 18%, the third straight year above historical norms but a lower figure than the gangbusters 25% returns of 2023 and 2024. AI euphoria is
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake
The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical
Pfizer Adds to Its Big Bet on Weight Loss Drugs
Health care stocks have been on a run lately, leading the S&P 500’s 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK)—and
5 Healthcare Plays Powering the Sector’s Big Comeback
After years of underperformance, the healthcare sector may finally be waking up. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV), which tracks the largest U.S. healthcare companies, has
Why AbbVie and Johnson & Johnson Could Outperform Pfizer
Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its closing price of
TrumpRx Brings Pfizer Into the Green—Is It a Buy?
Pfizer (NYSE: PFE) is no stranger to income investors. The drugmaker, famous for treatments including Lipitor, Viagra, and Zoloft, has now increased its dividend payout for 16 consecutive years
Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
After tanking in early August, the world’s most valuable pharmaceutical stock has roared back with a vengeance. That firm is Eli Lilly and Company (NYSE: LLY), the maker of the wildly popular
Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However
Pfizer is Locking in New Growth Through a New Acquisition
In the United States' healthcare sector, a new growth theme is emerging that nearly all companies want to capitalize on. Like artificial intelligence for technology stocks, weight loss drug
3 Long-Term Dividend Buys You Can Get for Under $50
Despite ongoing concerns about overvalued stocks, many value investors sleep well at night. That’s because the key to long-term value investing is total return, which includes a healthy, growing
Here's Why Pfizer Stock Is Still a Buy
Pfizer (NYSE: PFE) got a huge boost during the coronavirus pandemic thanks to its COVID-19 vaccine. Since that point, however, investors have soured on the stock, which has lost more than half its
3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year
Some investors are skeptical of companies with high dividend yields, since it sometimes signals that the dividend may be unsustainable. However, plenty of high-yield dividend stocks look solid
3 High-Yield Stocks to Buy Hand Over Fist in January
The S&P 500 index offers a paltry 1.1% dividend yield. By that standard, even consumer products giant Procter & Gamble's (NYSE: PG) 2.8% yield looks lofty. Here's why dividend lovers may want to
This Could Be 1 of the Best Pharmaceutical Stock-Buying Opportunities I've Seen in Years
It's been a miserable past three years for Pfizer (NYSE: PFE) shareholders. Although this drugmaker's stock was all the rage in the early days of the COVID-19 pandemic, as it co-created a
The Best Stocks to Invest $40 in to Start the New Year Off Right
Pfizer (NYSE: PFE) and Viking Therapeutics (NASDAQ: VKTX) underperformed in 2025. Both companies encountered some issues, some of which may linger throughout this year.
However, these drugmakers
The Top Stock to Buy With $30 for 2026
If you had only $30 to spend on a single share of a company, which one would you choose? Although price and value aren't the same thing on equity markets, the best stocks tend to attract enough
Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?
Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to
Down 55%, Should You Buy the Dip on Pfizer?
Pfizer (NYSE: PFE) is in the Wall Street doghouse. It is currently viewed as an also-ran in the drug sector, lagging far behind peers like Eli Lilly (NYSE: LLY) in various categories, including the
Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026
Pfizer's (NYSE: PFE) shares have been southbound for the last three years. And unfortunately for the company, it doesn't look like things will improve significantly in 2026. The pharmaceutical
Want Over $2,000 in Dividends Each Year? Invest $12,000 Each Into These 3 Stocks
Dividend stocks can be the ultimate investments to buy and forget about. They'll generate recurring income for your portfolio, even if you've forgotten you own them. What's important, however, is to
Pfizer's Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026?
A rising tide doesn't lift all boats. For example, a boat with gaping holes in its hull will sink regardless of how high the tide rises. Pfizer (NYSE: PFE) seemed to be the investing equivalent of
3 Drug Stocks to Buy at a Discount
Over short periods, Wall Street is largely driven by emotions. When there's a compelling story, such as the emergence of GLP-1 weight loss drugs in the pharmaceutical sector, investors tend to